Market Place
Sourcing Support
Alligator Bioscience Announces Exercise of Warrants Series TO 12
20 May 2025 //
ACCESSWIRE
Alligator: Paediatric Study Waiver for Mitazalimab Granted by EMA
20 May 2025 //
ACCESSWIRE
Alligator Bioscience Warrants Series TO 12 Trading Ends May 15
15 May 2025 //
ACCESSWIRE
Alligator Bioscience to Attend ASCO 2025 Annual Meeting
12 May 2025 //
ACCESSWIRE
Alligator Completes Ph3 GMP Manufacturing of Mitazalimab
09 May 2025 //
ACCESSWIRE
Alligator Secures TO 12 Program, Renegotiates Outstanding Loan
09 May 2025 //
ACCESSWIRE
Alligator Bioscience Updates Dividend Policy
08 May 2025 //
ACCESSWIRE
Aptevo Therapeutics Updates Program for Bispecific APVO711
08 May 2025 //
ACCESSWIRE
Change in Number of Shares and Votes in Alligator Bioscience AB
30 Apr 2025 //
ACCESSWIRE
Exercise Price Set for Warrant Series TO 12 in Alligator Bioscience
28 Apr 2025 //
ACCESSWIRE
Alligator Bioscience AB Reports Q1 2025 Financial Results
24 Apr 2025 //
ACCESSWIRE
Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer
23 Apr 2025 //
ACCESSWIRE
Notice of Annual General Meeting in Alligator Bioscience AB
02 Apr 2025 //
ACCESSWIRE
Alligator Bioscience Sets Record Date for Reverse Share Split
01 Apr 2025 //
ACCESSWIRE
Change in Number of Shares and Votes in Alligator Bioscience AB
31 Mar 2025 //
#N/A
Bulletin from Extraordinary Alligator Bioscience AB Meeting
27 Mar 2025 //
ACCESSWIRE
Alligator Bioscience Publishes Annual Report for 2024
27 Mar 2025 //
ACCESSWIRE
Alligator Bio Announces Clinical Development Leadership Transition
21 Mar 2025 //
ACCESSWIRE
Alligator Gets FDA Orphan Drug Tag For HLX22 In Gastric Cancer
20 Mar 2025 //
ACCESSWIRE
Alligator report survival benefit of mitazalimab with mFOLFIRINOX
27 Jan 2025 //
PHARMATIMES
Alligator Doses First Patient in Henlius Phase 3 Trial
04 Dec 2024 //
ACCESSWIRE
Exercise Price Set for Alligator Bioscience Warrants Series TO 9
02 Dec 2024 //
ACCESSWIRE
Orion and Alligator Bio amend agreement 2 bispecific antibodies
20 Nov 2024 //
PRESS RELEASE
Orion & Alligator Bioscience Amend Bispecific Antibodies Agreement
19 Nov 2024 //
#N/A
Aptevo and Alligator Present Positive ALG.APV-527 Data at SITC 2024
29 Oct 2024 //
ACCESSWIRE
Aptevo And Alligator Announce ALG.APV-527 Trial Data
16 Sep 2024 //
ACCESSWIRE
Aptevo And Alligator Present ALG.APV-527 Data For Solid Tumors At ESMO
13 Sep 2024 //
ACCESSWIRE
ASCO 2024: Alligator shares positive data for pancreatic cancer drug
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
07 Mar 2024 //
ACCESSWIRE
First-line Mitazalimab Plus Chemo Continues to Generate Responses in PDAC
27 Jun 2023 //
ONCOLIVE
Alligator & Aptevo Announce Dosing of First Patient with ALG.APV-527 in PI Trial
13 Feb 2023 //
ACCESSWIRE
Orion & Alligator reveal second stage of immuno-oncology research collaboration
03 Jan 2023 //
PHARMA TIMES
Alligator Announces +ve Interim Results from Mitazalimab OPTIMIZE-1 Ph 2 Trial
02 Jan 2023 //
PIPELINEREVIEW
Alligator Bioscience & Aptevo Announce Publication Highlighting ALG.APV-527 s
09 Nov 2022 //
ACCESSWIRE
Alligator Announces IND Approval for Second Phase 2 Clinical Trial of AC101
08 Nov 2022 //
PRESS RELEASE
Alligator Bioscience announces positive safety data from ATOR-1017 study
30 Sep 2022 //
PHARMATIMES
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued
19 Sep 2022 //
ACCESSWIRE
Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1
14 Sep 2022 //
MFN
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update
23 Mar 2022 //
PRNEWSWIRE
Alligator Bio initiates sponsored research agreement with UPENN
20 Jan 2022 //
PHARMABIZ
Alligator reports update on-going OPTIMIZE-1 phase Ib/II trial with mitazalimab
19 Jan 2022 //
PHARMABIZ
Alligator Announces Trial Update and Early Readout for ATOR-1017
15 Dec 2021 //
PRNEWSWIRE
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
08 Nov 2021 //
PRNEWSWIRE
Alligator is exploring financing alternatives to support phase II studies
02 Sep 2021 //
PRNEWSWIRE
Alligator announces Collaboration and License Agreement with Orion Corporation
18 Aug 2021 //
PRNEWSWIRE
Article on CD40 agonistic antibodies published in Expert Opinion
07 Jun 2021 //
BIOSPACE
Alligator`s mitazalimab shown to enhance cancer vaccine
06 May 2021 //
PRNEWSWIRE
Alligator & MacroGenics Enter into a Research Collaboration to Develop
16 Apr 2021 //
PRNEWSWIRE
Alligator and MacroGenics Enter into a Research Collaboration
15 Apr 2021 //
BIOSPACE
Alligator Bioscience appoints Søren Bregenholt as new CEO
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience appoints Søren Bregenholt as new CEO
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience publishes Annual Report for 2020
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience AB: Year-end Report January-December 2020
26 Feb 2021 //
PRNEWSWIRE
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
28 Dec 2020 //
PRNEWSWIRE
Alligator Bioscience recruits new Chief Medical Officer
28 Dec 2020 //
PRNEWSWIRE
Alligator seeks regulatory approval to begin ph II OPTIMIZE-1 of mitazalimab
28 Dec 2020 //
PHARMABIZ
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
28 Dec 2020 //
PRNEWSWIRE
Alligator Bioscience recruits new Chief Medical Officer
28 Dec 2020 //
PRNEWSWIRE
Alligator seeks regulatory approval to begin ph II OPTIMIZE-1 of mitazalimab
28 Dec 2020 //
PHARMABIZ
Alligator Bioscience`s IND for CD40 antibody mitazalimab gets US FDA approval
06 Dec 2020 //
PHARMABIZ
